PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Bioo Scientific

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Bioo Scientific's Newest Transduction Reagents Enable Targeted siRNA Delivery into Leukocytes - Bioo Scientific’s new huLeukoAim™ and moLeukoAim™ Transduction Reagents enable targeted delivery into leukocytes including lymphocytes (T and B cells), myeloid cells and granulocytes - BiooScientific.com
Bioo Scientific's Newest Transduction Reagents Enable Targeted siRNA Delivery into Leukocytes

 

NewswireToday - /newswire/ - Austin, TX, United States, 2012/09/12 - Bioo Scientific’s new huLeukoAim™ and moLeukoAim™ Transduction Reagents enable targeted delivery into leukocytes including lymphocytes (T and B cells), myeloid cells and granulocytes - BiooScientific.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Bioo Scientific launched the innovative huLeukoAim™ and moLeukoAim™ Transduction Reagents which offer targeted delivery into leukocytes including lymphocytes (T and B cells), myeloid cells and granulocytes resulting in efficient gene silencing in mouse and human cells. siRNA therapy is a promising approach for treatment of leukocytic disorders and infections; however, delivery reagents that can target these cell types have not been available until now.

The huLeukoAim and moLeukoAim Transduction Reagents provide a safe and nontoxic approach for the delivery of siRNA and potentially other therapeutic molecules to leukocytes and have been validated with HL-60, CCRF-CEM and T-ALL cell lines.

According to Dr. Sandesh Subramanya, Senior Scientist at Bioo Scientific,“Our team of scientists at Bioo Scientific is developing innovative transduction reagents that offer cell-specific delivery of siRNA and miRNA to address the current bottleneck that impedes therapeutic applications of RNAi.”

The huLeukoAim and moLeukoAim Transduction Reagents are the latest additions to Bioo Scientific’s line of targeted delivery reagents which also include the popular NeuroAIM™ and MyeloAim™ Transduction Reagents and the T3™-Max Conjugation Kit.

About Bioo Scientific Corporation

Founded in 2003, Bioo Scientific Corporation (biooscientific.com) is an Austin, TX based biotechnology company that provides innovative solutions to the life science and food safety industries. Bioo Scientific’s products are used around the world and can be purchased both directly or through our global distribution network that markets our products in more than 100 countries.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Bioo Scientific

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Bioo Scientific's Newest Transduction Reagents Enable Targeted siRNA Delivery into Leukocytes

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Dawn Obermoeller - BiooScientific.com 
512-707-8993 dawno[.]biooscientific.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Bioo Scientific securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Bioo Scientific / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)